Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/27/2010US20100129429 Inhibition of autophagy genes in cancer chemotherapy
05/27/2010US20100129425 Vaginal delivery system for mirtazapine
05/27/2010US20100129423 Device made at least partially of n-acetylchitosan with controlled biodissolution
05/27/2010US20100129420 Methods and devices to accelerate wound healing in thoracic anastomosis applications
05/27/2010US20100129418 Method of inducing negative chemotaxis using an ellagitannin or gallotannin
05/27/2010US20100129417 Dihydroxybenzoate Polymers and Uses Thereof
05/27/2010US20100129414 Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment
05/27/2010US20100129388 Protective proteins of s. agalactiae, combinations thereof and methods of using the same
05/27/2010US20100129378 Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
05/27/2010US20100129372 Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
05/27/2010US20100129367 Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
05/27/2010US20100129366 Thiazole inhibitors of cyclooxygenase
05/27/2010US20100129364 Combination therapy for the treatment of ocular neovascular disorders
05/27/2010US20100129363 Methods and compositions using pde4 inhibitors for the treatment and management of cancers
05/27/2010US20100129353 Combination and treatment for multiple sclerosis
05/27/2010US20100129352 Novel pharmaceutical composition
05/27/2010US20100129350 Triazine Derivatives, Compositions Containing Such Derivatives, and Methods of Treatment of Cancer and Autoimmune Diseases Using Such Derivatives
05/27/2010US20100129348 Method for decreasing depression by inhibiting the activity of alpha 1b subunit of n-type calcium channel
05/27/2010US20100129345 Screening method for prokinetic agent
05/27/2010US20100129343 Use Of A Compound For Enhancing The Expression Of Membrane Proteins On The Cell Surface
05/27/2010US20100129340 Methods and materials for the generation of regulatory t cells
05/27/2010US20100129332 Methods and pharmaceutical compositions for healing wounds
05/27/2010US20100129331 Disacchrides for the treatment of tendons, ligaments, and bones
05/27/2010US20100129321 Diaryl urea for treating virus infections
05/27/2010US20100129320 Quinoline derivatives for modulating dna methylation
05/27/2010US20100129319 Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor
05/27/2010US20100129317 Azole nucleosides and use as inhibitors of rna and dna viral polymerases
05/27/2010US20100129311 Phenylalanine amide inhibitors of atp-sensitive potassium channels
05/27/2010US20100129310 Stabilized desloratadine composition
05/27/2010US20100129309 Amine polymer compositions
05/27/2010US20100129308 Polymers Functionalized with Ion-Specific Recognition Elements
05/27/2010US20100129291 Nicotinic desensitizers and methods of selecting, testing, and using them
05/27/2010US20100129288 Gliomedin, Fragments Thereof and Methods of Using Same
05/27/2010DE102008059133A1 Difluorphenyl-diacylhydrazid-derivate Difluorophenyl diacylhydrazide derivatives
05/27/2010DE102007014947B4 Stabilisierte wässrige Lösungen von Ergolinverbindungen The stabilized aqueous solutions of ergoline compounds
05/27/2010CA2747188A1 Novel antithrombotic diadenosine tetraphosphates and related analogs
05/27/2010CA2744425A1 Quinazoline inhibitors of bace 1 and methods of using
05/27/2010CA2744407A1 New formulations with anti-neoplastic activity
05/27/2010CA2744388A1 Compositions and methods for treating or preventing radiation injury
05/27/2010CA2744383A1 Adamantyl benzamide compounds
05/27/2010CA2744377A1 Directly compressible high functionality granular dibasic calcium phosphate based co-processed excipient
05/27/2010CA2744351A1 New compounds
05/27/2010CA2744343A1 6, 7 -dihydro- 5h- pyrrolo [3, 4-d] pyrimidin-4-yl] -quinolin-3 -ylamine compounds useful as faah modulators and uses thereof
05/27/2010CA2744308A1 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
05/27/2010CA2744307A1 Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
05/27/2010CA2744278A1 Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
05/27/2010CA2744211A1 Wet granulation of tenofovir, emtricitabine and efavirenz
05/27/2010CA2744189A1 Tgr5 modulators and methods of use thereof
05/27/2010CA2744158A1 Anti-angiogenesis therapy for the treatment of breast cancer
05/27/2010CA2744154A1 Pyrazolopyridine pi3k inhibitor compounds and methods of use
05/27/2010CA2744135A1 Tgr5 modulators and methods of use thereof
05/27/2010CA2744031A1 Anticancer combination comprising docetaxel and an antisense oligonucleotide
05/27/2010CA2744030A1 Combination therapy for the treatment of cancer
05/27/2010CA2744016A1 Treatment of amyotrophic lateral sclerosis
05/27/2010CA2744012A1 Glycogen synthase kinase-3 beta inhibitors containing 7-hydroxy-benzoimidazole-4-yl-methanone derivatives
05/27/2010CA2743959A1 Liposomal composition for convection-enhanced delivery to the central nervous centre
05/27/2010CA2743913A1 Inhibition of apoe cleavage activity in the treatment of apoe-related disorders
05/27/2010CA2743903A1 Compounds for treating parasitic disease
05/27/2010CA2743856A1 Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof
05/27/2010CA2743782A1 Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde o-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
05/27/2010CA2743724A1 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
05/27/2010CA2743723A1 Inhibitors of diacylglycerol acyltransferase
05/27/2010CA2743609A1 Inhibitors of diacylglycerol acyltransferase
05/27/2010CA2743584A1 Lactams as beta secretase inhibitors
05/27/2010CA2743562A1 Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
05/27/2010CA2743553A1 Dimeric 1-arylpyrazole derivatives
05/27/2010CA2743551A1 Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
05/27/2010CA2743497A1 Inhibitors of diacylglycerol acyltransferase
05/27/2010CA2743436A1 Pathways to generate hair cells
05/27/2010CA2743261A1 Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
05/27/2010CA2743157A1 .alpha.-keto peracids and methods for producing and using the same
05/27/2010CA2743000A1 A triazolothiadiazole inhibitor of c-met protein kinase
05/27/2010CA2742947A1 Antioxidant
05/27/2010CA2742946A1 Antioxidant
05/27/2010CA2742909A1 Anti-wrinkle agents
05/27/2010CA2742903A1 Novel bis-amides as antimalarial agents
05/27/2010CA2742869A1 Fluorination of organic compounds
05/27/2010CA2742790A1 Novel forms of an indazolo [5,4-a] pyrrolo [3,4-c] carbazole compound
05/27/2010CA2742692A1 Use of escin for treatment of type iv hypersensitivity reaction
05/27/2010CA2742023A1 Polar quinazolines as liver x receptors ( lxrs ) modulators
05/27/2010CA2741986A1 Method and apparatus for manure treatment
05/27/2010CA2741839A1 1-oxa-8-azaspiro [4,5] decane-8-carboxamide compounds as faah inhibitors
05/27/2010CA2741511A1 Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
05/27/2010CA2741041A1 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
05/27/2010CA2741038A1 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
05/27/2010CA2739900A1 Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
05/27/2010CA2739390A1 Fat emulsion for artificially feeding seriously ill intensive care patients
05/27/2010CA2738732A1 Pharmaceutical composition of a potent hcv inhibitor for oral administration
05/27/2010CA2738616A1 Aerosol formulation for the inhalation of beta agonists
05/27/2010CA2734284A1 Pyrazolone derivative formulations
05/27/2010CA2708334A1 Process for recovering florfenicol from pharmaceutical compositions
05/26/2010EP2189537A1 Detection and treatment of schizophrenia
05/26/2010EP2189522A1 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
05/26/2010EP2189462A1 Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases
05/26/2010EP2189461A1 Crystalline irinotecan hydrochloride and methods for the preparation thereof
05/26/2010EP2189459A1 Stable crystalline salt of 5-methyll-(6S)-tetrahydrofolic acid
05/26/2010EP2189458A1 Aryl amide compound as an acetyl coenzyme A carboxylase inhibitor
05/26/2010EP2189454A1 Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
05/26/2010EP2189453A1 Rocaglaol derivatives as cardioprotectant agents
05/26/2010EP2189452A1 Ascorbic acid derivative or salt thereof, method for producing the same, and cosmetic preparation
1 ... 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 ... 7860